Health Research Methods, Evidence, and Impact

Michael Gent

BSc (Durham), MSc (Durham), DSc (Durham)

Professor Emeritus, Department of Health Research Methods, Evidence, and Impact








Michael Gent was born and educated in England. On leaving University, he worked at ICI Ltd., Pharmaceuticals Division, for three years as a research statistician. He then moved to Bradford University leaving at the rank of Senior Lecturer after nine years. He joined the Department of CE&B in 1969 as an Associate Professor: he was made a Professor in 1973; was Chair of the Department ('73-'79); and was Associate Dean of Health Sciences (Research) ('79-'83). He served on the Scientific Review Committee of the Canadian Heart Foundation ('71-'80), including terms as Vice- Chairman ('75-'77) and Chair ('77-'80). He also served the Ontario Heart and Stroke Foundation as a member of the Medical Research Committee ('81-'83), Research Priorities Committee ('85-'87), and as a Director ('85-'87). He has had extensive involvement with the Medical Research Council of Canada; as chair of the MRC Committee for Clinical Trials ('82-'86), Member of the Council ('82-'89), and Vice-President of the Council ('87-'89). He was Chair of the Health Research Personnel Development Committee, Ontario Ministry of Health ('81-'87). He has served on the Editorial Board of Applied Statistics, Annals of Internal Medicine, and of Stroke; on several working groups and review committees for the National Institutes of Health; and on the Executive Committee of the International Society for Clinical Biostatistics ('78-'80) and the Board of Directors for the Society for Clinical Trials ('84-'88). He was elected a Fellow of the American Statistician Association in 1981. In his early career he functioned primarily as an applied biostatistician involved in a broad spectrum of collaborative research in both laboratory and clinical settings. His interests broadened to issues of general methodology and organization in randomized controlled trials, with particular emphasis in the evaluation of antiplatelet drugs in cerebral and myocardial ischemia and the evaluation of anticoagulants in the prophylaxis and treatment of venous thrombosis. He has published extensively and,in particular,he co-authored two papers with Charles Dunnett which laid the foundation for current strategies for non-inferiority testing.He ranks in the top 2% of the Institute for Scientific Information's most highly cited authors for Clinical Medicine.He was the founding Director of the Clinical Trials Methodology Group at the Henderson Research Centre, a role that he filled for thirteen years before retiring in 2002.He was inducted into the Faculty of Health Sciences' Community of Distinction in 2006. A chair in his name, the Michael Gent Chair in Healthcare Research, was established in 2008.He received an honorary degree of Doctor of Science from McMaster in 2010.

Selected Publications

  1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
  2. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-29.
  3. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG and the CATS Group. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
  4. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH. Aspirin, sulfinpyrazone, or both in unstable angina; Results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
  5. Gent M, Blakely JA, Hachinski V, Robers RS, Barnett HJM, Bayer NH, Carruthers SG, Collins SM, Gawel MG, Giroux-Klimek M, Hopkins M, Jain P, Lamy M, Meloche JP, Saerens E, Sicurella J, Turpie AGG. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985;16:416-24.
  6. Gent M, Sackett DL. The qualification and disqualification of patients and events in long-term cardiovascular clinical trials. Thromb Haemost 1979;41:123-34.
  7. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2.
  8. The Anturance Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N Engl J Med 1978;298:289-95.
  9. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-9.
  10. Genton E, Gent M, Hirsh J, Harker LA. Platelet inhibiting drugs in the prevention of clinical thrombotic disease: A review N Engl J Med 1975;293:Part 1, 1174-78; Part 2, 1236-40; Part 3,1296-1300.

Seach for citations for Dr. Gent on PubMed